Nvidia’s desktop AI supercomputer now available to the general public
Investing.com -- Marker Therapeutics Inc (NASDAQ:MRKR) stock surged 15% in premarket trading Tuesday after the company reported positive clinical data from its Phase 1 APOLLO study testing MT-601 in lymphoma patients.
The clinical-stage immuno-oncology company revealed that its multi-antigen recognizing T cell therapy demonstrated a 66% objective response rate in patients with Non-Hodgkin Lymphoma (NHL), with 50% achieving complete responses. The treatment also showed a favorable safety profile across all evaluated doses.
The study included 24 B-cell lymphoma patients treated across seven U.S. clinical sites, comprising 15 patients with NHL and 9 with Hodgkin Lymphoma (HL). Among the 12 NHL patients evaluated, eight showed objective responses, with six demonstrating complete responses. These NHL patients had previously undergone a median of five prior lines of therapy, including CAR-T cells and bispecific antibodies.
For Hodgkin Lymphoma patients, who had received a median of eight prior treatment lines, seven out of nine showed objective responses, with one complete response.
The company reported durable responses ranging from 3 to 24 months, with five patients showing continued response for six months or longer, including three patients with durability of 12 months or more.
MT-601 demonstrated a robust safety profile with no dose-limiting toxicities reported at the highest dose level (400x106 cells). Only two Grade 1 cytokine release syndrome events were observed, which required no treatment, and no immune effector cell-associated neurotoxicity syndrome (ICANS) was reported.
The company is positioning MT-601 as a potential treatment option for patients who have relapsed after anti-CD19 CAR-T cell therapy or for whom such therapy is not an option.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.